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Abstract: The species of the genus Trillium (Melanthiaceae alt. Trilliaceae) include perennial herbs
with characteristic rhizomes mainly distributed in Asia and North America. Steroids and saponins
are the main classes of phytochemicals present in these plants. This review summarizes and discusses
the current knowledge on their chemistry, as well as the in vitro and in vivo studies carried out on the
extracts, fractions and isolated pure compounds from the different species belonging to this genus,
focusing on core biological properties, i.e., cytotoxic, antifungal and anti-inflammatory activities.
Keywords: bioactive phytochemicals; cytotoxic activity; anti-inflammatory activity; analgesic activity;
antifungal activity
1. Introduction
Natural products obtained from plants have played remarkable role in drug discovery and
improvement of health care system [1–6]. According to the World Health Organization (WHO)
estimate, about 80% of world population relies on natural sources for their primary health care need
while the remaining 20% of the population uses integrated natural sources [7]. Even at the dawn of
21st century, 11% of the 252 drugs considered as basic and essential by the WHO were exclusively of
flowering plants origin [8]. At present, the area of cancer and infectious diseases are mostly dependent
on natural products, and among the 175 approved anti-cancer drug molecules, 85 (49%) are either
natural products or their derivatives [3].
In scientific literature around the world, more than 35,000 plant species have been reported to
be used in different human cultures for medicinal purposes [9]. Nevertheless, this number could be
much higher, as knowledge of indigenous use of medicinal plants mainly passes verbally from one
generation to another and largely remains undocumented. Among the 250,000 reported higher plant
species, only 5–15% has been scrutinized for their bioactive molecules [10]. Therefore, medicinal plants
represent an area under focus since their secondary metabolites encompass a significant number of
drugs used in current therapeutics and their potential as source of new medicines is beyond any doubts.
Saponins are steroid or triterpene glycosides widely distributed in the plants that possess
hemolytic properties and poisonous effects [11]. The aglycone part (sapogenin) of saponins may have
steroid or triterpenoid nuclei, based on whom saponins are generally classified. Steroidal saponins are
less common and usually found in monocotyledonous plants as compared to triterpenoid saponins,
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which are extensively distributed and found in dicotyledonous plants [12]. The basic skeleton of
steroidal sapogenins (27C) may be either 6-ring spirostane or 5-ring furostane, while triterpenoid
sapogenins (30C) are structurally different and often consist of five or rarely four units. In general,
at C-3 of aglycone moiety, the glycone (sugar) is attached, including one to several monosaccharide
units. The attached sugar chains may be from one to three, either straight, branched or both.
The presence of different substituents in the sapogenin as well as the composition, linkage and
number of sugar moieties account for structural diversity of saponins [13].
Similarly, the structural complexity of the saponins accounts for their diverse physicochemical,
pharmacological and biological properties as well as their commercial relevance as promising molecules
with several applications in food, cosmetic, pharmaceutical and health fields [14]. Indeed, saponins
have been investigated for the development of new natural medicines and to prove the efficacy
of traditional herbal medicines. Crude drugs containing saponins that have less irritating effects
following oral administration are generally used as expectorant and antitussive agents [11]. It is
worth mentioning that many saponins have been reported to exhibit significant anti-inflammatory,
anti-nociceptive, antipyretic, anti-allergic and anti-cancer properties [15,16].
Steroids are a group of secondary metabolites derived from cholesterol, showing diverse chemical
structure and biological functions. Almost all steroid molecules possess the same basic perhydroxyl
cyclopentenophenanthrene skeleton. The differences in the basic skeleton and the attachment of
different groups result in various classes of steroids [17]. Steroids have many pharmacological
applications and the research is continuing to find out about these metabolites, as potential lead
compounds in drug design and discovery [18]. For instance, ecdysteroids are polyhydroxy steroids
produced by certain plants including those belonging to the genus Trillium. Plants containing
ecdysteroids possess noticeable pharmacological properties as anabolic, antidiabetic, analgesic,
anti-inflammatory and anthelmintic activities [18,19].
2. The Genus Trillium
Trillium is the most important genus belonging to the family Melanthiaceae alt. Trilliaceae. Steven
Elliott in 1817 wrote: “The family Trilliaceae is an attractive one. A spiral of leaves at the peak of a stem,
sustaining solitary flower; it encloses and covers numerous species”. The genus Trillium consists of
perennial herbs with characteristic rhizomes that are horizontal or erect, semierect, branched or faintly
unbranched, compressed to shortened, elongated to bulky and fleshy, distal end pointed or premorse;
the apex bears large terminal shoot/bud. Stem has leaf-sheaths and brown scales at the base. Leaves
are three located at the top of the main stem. Flowers are totally to partly pedicellate, sessile and
syncarpous. The genus comprises about forty-eight interrelated species in eastern North America and
temperate areas of Asia, as well as in western North America [20]. Most of the Trillium species are
related with deciduous forests (Arcto-Tertiary flora), which have continued with remarkable changes
in geographical ranges since the early Tertiary period in the northern hemisphere. At present, Trillium
species are limited to one of three geographical areas: Asia, western North America and eastern North
America [21]. Some important species of the genus Trillium with specific characteristics [22–24] are
reported in Table 1.
Table 1. Common species of the genus Trillium.








• Dwarf white Trillium United States March–April
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• Least Trillium United States March–May
5
Trillium grandiflorum (Michx.) Salisb.
• Great white Trillium
• White wake-robin Mountains of Virginia (U.S.) April–June
6
Trillium ovatum Pursh








• Round-leaved Trillium North America April–May
9
Trillium simile Gleason
• Sweet white Trillium North America April–May
10
Trillium lancifolium Raf.
• Lance leaved Trillium North America February–May
11 Trillium kamtschaticum Pall. Ex Miyabe Korea, Japan, Russia, North America, China April–June
12 Trillium tschonoskii Maxim. Bhutan, Japan, Korea, China July–August
13 Trillium taiwanense S.S.Ying Taiwan, China May–June
14
Trillium parviflorum V.G.Sokup
• Small flowered Trillium North America March–May
15 Trillium govanianum Wall. Bhutan, India, Nepal, China, Pakistan April–August
3. Phytochemicals of the Genus Trillium
The genus Trillium is a rich source of bioactive phytochemicals as steroids, saponin derivatives
and flavonoids [25–29]. Thus far, several steroidal saponins have been isolated and purified from the
plants belonging to this genus and, at present, novel metabolites/phytochemicals from Trillium ssp.
are investigating using the latest technologies [30–34]. The secondary metabolites/phytochemicals of
species belonging to the genus Trillium are reported in Table 2.
Table 2. List of phytochemicals isolated from genus Trillium.
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indicate the promising potential of crude extracts, solvent fractions and isolated pure compounds. 
[35]
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The rhizomes of T. erectum, named beth roots, have been used in folk medicine for the treatment
of hemorrhages from uterus, urinary tract and lungs [43]. T. tschonoskii has been traditionally used in
China for at least one thousand years [44,45]. Dried rhizomes of this plant species have been used as
herbal remedy for treatment of hypertension, neurasthenia, giddiness, headache, removing carbuncles
and ameliorating pains [46,47]. The anticancer and pro-apoptotic activities of n-BuOH extract against
human lung cancer cells have also been demonstrated [45].
The ethanol, ethyl acetate and butanol extracts of T. tschonoskii significantly suppressed the edema
of rat hind paw swelling elicited by injection of carrageenan [48]. Finally, T. tschonoskii improved
learning and memory in rats, by enhancing the expression of anti-oxidase enzymes [49].
Ethanol extract from rhizomes and aerial parts of T. grandiflorum exhibited antifungal activity [40].
The rhizome of T. govanianum is commonly known as “matar zela” or “teen patra” in Pakistan,
and “nag chatri” in India [19]. In folk medicine, T. govanianum is used to cure dysentery and boils;
in wound healing, and menstrual and sexual disorders; and as anti-inflammatory and antiseptic
agent [50]. The powdered roots are used as body and sexual tonic [51]. Noteworthy, analgesic,
anti-inflammatory, antifungal, free radical scavenging, β-glucuronidase inhibitory activities as well
as cytotoxicity against prostate and cervical carcinoma cells of T. govanianum have been recently
reported [19,29,50].
5. Bioactivities of the Genus Trillium Phytochemicals
The isolated secondary metabolites of the genus Trillium mostly belong to the chemical class of
steroidal saponins and steroids, including ecdysteroids, even if flavonoids and trihydroxy fatty acids
have also been reported. The isolated compounds exhibited a remarkable potential when tested in
different in vitro and in vivo assays. Thus far, among the tested steroidal saponins, both spirostanol
and furostanol saponins, many of them exhibited relevant cytotoxicity against different cancer cell lines,
few showed high potential against tested fungal strains, while some of them possessed antioxidant
and COX-2 inhibitory activity, as reported in Table 3.
Table 3. Bioactivities of the genus Trillium phytochemicals.





Cytotoxic, anti-proliferative and morphological
effects on lung cancer cell line [52]; cytotoxicity
against malignant sarcoma cells [53]
7-β-hydroxy trillenogenin 1-O-β-D-apiofuranosyl-(1→3)-
α-L-rhamnopyranosyl-(1→2)-[β-D-xylopyranosyl-(1→3)]-
α-L-arabinopyranoside, Trillenoside A (compound 52)
Inhibitory activity against COX-2 in in
macrophagocytes of the mouse abdominal cavity





Cytotoxicity against HL-60 human promyelocytic





Cytotoxicity against HL-60 human promyelocytic





Cytotoxicity against HL-60 human promyelocytic





Cytotoxicity against HL-60 human promyelocytic





Cytotoxicity against HL-60 human promyelocytic
leukemia cells, IC50 (µg/mL) = 2.89 ± 0.24 [26]
Molecules 2017, 22, 2156 12 of 15
Table 3. Cont.







(compound 31) boeassoside E (compound 32) 7, 8,
9-trihydroxy-(10Z)-10-octadecenoic acid (compound 48)
Antifungal activity against Aspergillus niger,
A. flavus, Candida albicans, C. glabrata, Trichophyton
rubrum [19,28]
pennogenin (compound 35), borassoside E (compound 32),





Cytotoxicity against human colorectal cancer cells




Cytotoxicity against human colorectal cancer cells




Cytotoxicity against human colorectal cancer cells






Antifungal activity against Candida albicans MIC
(µg/mL) = 1.56 [40]
In addition, the biological activities of steroidal saponins mainly depend on their aglycone
moieties (steroidal sapogenins) as well as the number and structure of monosaccharide units in their
sugar chains. A slight structural diversity endorses a significant difference on their antifungal and
cytotoxic properties, i.e., spirostanol saponins exhibit a higher antifungal potential in comparison to
their analogous furostanol saponins. Therefore, it is worth mentioning that further detailed studies on
the structure–activity relationships (SAR) and molecular/biochemical targets of steroidal saponins are
required to explore the therapeutic potential of this important class of natural products as leads for
new drug discovery.
6. Conclusions and Future Perspectives
Thus far, more than 40 steroidal saponins having spirostane and furostane type aglycons from
the genus Trillium have been isolated. Their structure was determined by the use of spectroscopic
techniques, including fast atom bombardment mass spectrometry (FABMS) and extensive 2D nuclear
magnetic resonance (NMR) experiments (COSY, TOCSY, NOESY, HSQC, and HMBC). The existing data
strongly suggest that plants belonging to the genus Trillium are rich source of steroids and saponins
and possess a therapeutic potential in the management of cancers, fungal infections, inflammatory
and painful disorders. Noteworthy, most of the plant species are still unexplored, and some are
under investigation; therefore, further comprehensive studies are needed to screen new sources
of phytochemicals to develop promising phytotherapeutics effective in the treatment of chronic
degenerative and infectious diseases. Finally, the most promising Trillium secondary metabolites have
to be investigated in humans, in properly designed randomized clinical trials, to reach the highest
level of clinical evidence.
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